Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
Table of Contents

Change in Control.  In the event of a change in control where the acquiror does not assume awards granted under the 2004 plan and does not substitute substantially similar awards for those outstanding under the 2004 plan, awards issued under the 2004 plan will terminate upon the consummation of the transaction. Under the 2004 plan, a change in control is generally defined as:
  •      a merger, consolidation or other business combination transaction with or into another corporation, entity or person, or the direct or indirect acquisition (including by way of a tender or exchange offer) by any person, or persons acting as a group, of beneficial ownership or a right to acquire beneficial ownership of shares representing a majority of the voting power of the then outstanding shares of our capital stock; or
  •      a sale of all or substantially all of our assets.
Amendment and Termination of the 2004 plan.  Our board of directors may terminate, amend or modify the 2004 plan. However, stockholder approval of any amendment to the 2004 plan will be obtained to the extent necessary and desirable to comply with any applicable law, regulation, or stock exchange rule. If not terminated earlier by our board of directors the 2004 plan will terminate on the tenth anniversary of the date of its initial adoption by our board of directors.
Outstanding Equity Awards at Fiscal Year-End
The following table presents the outstanding equity awards held by each of the named executive officers as of December 31, 2006.
    Option Awards  
                Equity Incentive
                Plan Awards: Number
    Number of
    Number of
    of Securities
    Unexercised Options
    Unexercised Options
    Option Exercise
    (#)     (#)     Options
  Exercisable     Unexercisable     (#)     ($)     Date  
Gary D. Tollefson, M.D., Ph.D. 
    408,434       (1)           0.30       5/26/2015  
      666,666       666,666 (1)             0.30       5/26/2015  
      25,000       375,000 (1)             1.00       9/28/2016  
Anthony A McKinney
    294,574       (2)           0.05       3/10/2015  
      15,625       234,375 (1)             1.00       9/28/2016  
Graham K. Cooper
    525,888       (1)           0.35       7/12/2016  
Eduardo Dunayevich, M.D. 
          500,000 (2)           1.00       9/28/2016  
Ronald P. Landbloom, M.D. 
          500,000 (2)           1.00       9/28/2016  
Lynne Rollins
(1) 1/48th of the total number of shares subject to the option vest monthly.
(2) 25% of the total number of shares subject to the option vest at the end of the first year, the remainder vest 1/36th per month thereafter.